Early detection of cancer using circulating tumor DNA: biological, physiological and analytical considerations
- 22 December 2019
- journal article
- review article
- Published by Taylor & Francis in Critical Reviews in Clinical Laboratory Sciences
- Vol. 57 (4) , 253-269
Abstract
Early diagnosis of cancer improves the efficacy of curative therapies. However, due to the difficulties involved in distinguishing between small early-stage tumors and normal biological variation, early detection of cancer is an extremely challenging task and there are currently no clinically validated biomarkers for a pan-cancer screening test. It is thus of particular significance that increasing evidence indicates the potential of circulating tumor DNA (ctDNA) molecules, which are fragmented segments of DNA shed from tumor cells into adjacent body fluids and the circulatory system, to serve as molecular markers for early cancer detection and thereby allow early intervention and improvement of therapeutic and survival outcomes. This is possible because ctDNA molecules bear cancer-specific fragmentation patterns, nucleosome depletion motifs, and genetic and epigenetic alterations, as distinct from plasma DNA originating from non-cancerous tissues/cells. Compared to traditional biomarkers, ctDNA analysis therefore presents the distinctive advantage of detecting tumor-specific alterations. However, based on a thorough survey of the literature, theoretical and empirical evidence suggests that current ctDNA analysis strategies, which are mainly based on DNA mutation detection, do not demonstrate the necessary diagnostic sensitivity and specificity that is required for broad clinical implementation in a screening context. Therefore, in this review we explain the biological, physiological, and analytical challenges toward the development of clinically meaningful ctDNA tests. In addition, we explore some approaches that can be implemented in order to increase the sensitivity and specificity of ctDNA assays.Keywords
This publication has 157 references indexed in Scilit:
- Analysis of Circulating Tumor DNA to Monitor Metastatic Breast CancerNew England Journal of Medicine, 2013
- Screening for Prostate Cancer: A Review of the Evidence for the U.S. Preventive Services Task ForceAnnals of Internal Medicine, 2011
- High Fragmentation Characterizes Tumour-Derived Circulating DNAPLOS ONE, 2011
- Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic ScreeningNew England Journal of Medicine, 2011
- A DNA methylation fingerprint of 1628 human samplesGenome Research, 2011
- Detection and quantification of rare mutations with massively parallel sequencingProceedings of the National Academy of Sciences, 2011
- Origin and quantification of circulating DNA in mice with human colorectal cancer xenograftsNucleic Acids Research, 2010
- Analysis of Mutations in DNA Isolated From Plasma and Stool of Colorectal Cancer PatientsGastroenterology, 2008
- Circulating mutant DNA to assess tumor dynamicsNature Medicine, 2008
- Circulating microRNAs as stable blood-based markers for cancer detectionProceedings of the National Academy of Sciences of the United States of America, 2008